Clinical trialNCT00500539CompletedPhase 3Interventional

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

SponsorNovartisEnrollment155Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age or older, with no previous exposure to the drug (omalizumab naïve patients). The secondary objective of this study is to assess the safety of the liquid formulation of omalizumab in the same patients.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jose Bardelas, MD
Allergy and Asthma center of North Carolina, PA, High Point, NC 27262
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site,
Buenos Aires, Argentina
Novartis Investigative Site,
Corrientes, Argentina
Novartis Investigative Site,
Mendoza, Argentina

Germany

Novartis Investigator Site
Nuremberg, Germany

United States

Allergy & Immunology Associates, Ltd
Scottsdale, Arizona, United States
California Allergy and Asthma Medical Group
Palmdale, California, United States
Allergy Associates Medical Group, Inc,
San Diego, California, United States
Bensch Research Associates
Stockton, California, United States
1st Allergy and Clinical Research Center
Centennial, Colorado, United States
Innovative Research of West Florida, Inc.
Largo, Florida, United States
Georgia Pollen
Albany, Georgia, United States
Kansas City Allergy & Asthma
Overland Park, Kansas, United States
Asthma and Allergy Specialists, Pa
Minneapolis, Minnesota, United States
: the Clinical Research Center, Llc
St Louis, Missouri, United States
Allergy, Asthma and Clinical Immunology
Brick, New Jersey, United States
Asthma & Allergy Research of Nj, Inc.
Mount Laurel, New Jersey, United States
Nassau Chest Pysicians, Pc
Massapequa, New York, United States
Allergy and Asthma Center of Nc, Pa
High Point, North Carolina, United States
Allergy Center at Brookstone
Columbus, Ohio, United States
Toledo Center for Clinical Research
Sylvania, Ohio, United States
Asthma and Allergy Center
Toledo, Ohio, United States
the Corvallis Clinic, Pc
Corvallis, Oregon, United States
Allergy, Asthma & Dermatology Research Center
Lake Oswego, Oregon, United States
Clinical Research Institute of Southern Oregon, Pc
Medford, Oregon, United States
Allergy & Asthma Specialists, Pc
Blue Bell, Pennsylvania, United States
Asthma Allergy & Pulmonary Associates, Pc
Philadelphia, Pennsylvania, United States
Aapri Clinical Research Institute
Providence, Rhode Island, United States
North Texas Institute for Clinical Trials
Fort Worth, Texas, United States
Allergy and Asthma Associates
Houston, Texas, United States
Clinical Trials of North Houston
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omalizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2007
Primary completion: 30 Sept 2008
Completion: 30 Sept 2008
Last update posted: 2 Jun 2011
Registered enrollment: 155
Registry id: NCT00500539

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.